With its rep on the line, Celgene's newly-filed safety study spurs fresh worries over fate of ozanimod
After blundering its way into an ugly setback at the FDA with its highly anticipated multiple sclerosis drug ozanimod, Celgene is triggering fresh questions about the future of this frequently touted blockbuster-to-be with a slate of newly filed clinical trials aimed at further exploring possible safety issues. And that has at least one prominent analyst wondering if he will need to eventually recalculate the timing — and chances of success — of the marketing pitch.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.